In order to go it alone with antibody drug conjugate (ADC) IMMU-132, Immunomedics Inc. would need to immediately raise $150 million to cover the phase III trial in triple-negative breast cancer (TNBC) and another $125 million to build a sales force, which is one reason why the company signed a potential $2 billion deal with Seattle Genetics Inc. focused on the drug more specifically known as sacituzumab govitecan, said Jason Aryeh, vice chairman of the board and chairman of the transaction committee.